GU Cancers 2021 | OS of patients with mCRPC with PTEN loss-of-function identified by genomic profiling

Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, discusses the overall survival (OS) of patients with metastatic castration-resistant prostate cancer (mCRPC) who have PTEN tumor suppressor gene loss-of-function. When determined by genomic profiling, PTEN loss-of-function was found to be associated with a shorter overall survival and a 30% higher risk of death compared to patients in the PTEN non-loss-of-function group. Dr Gupta describes the patient characteristics in each cohort and suggests additional studies are warranted in this area to further improve patient outcomes. This interview took place during the 2021 Genitourinary Cancers Symposium.